Article
Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jun 2017
Guo J, Carvajal R D, Dummer R, Hauschild A, Daud A, Bastian B C, Markovic S N, Queirolo P, Arance A, Berking C, Camargo V, Herchenhorn D, Petrella T M, Schadendorf D, Sharfman W, Testori A, Novick S, Hertle S, Nourry C, Chen Q, Hodi F S
Abstract excerpt
BACKGROUND: The single-arm, phase II Tasigna Efficacy in Advanced Melanoma (TEAM) trial evaluated the KIT-selective tyrosine kinase inhibitor nilotinib in patients with KIT-mutated advanced melanoma without prior KIT inhibitor treatment. PATIENTS AND METHODS: Forty-two patients with KIT-mutated advanced melanoma were enrolled and treated with nilotinib 400 mg twice daily. TEAM originally included a comparator arm...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.